These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11070154)

  • 41. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
    Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
    Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
    Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics].
    Li HH; Ma F; Zeng X; Wang JY; Yuan P; Fan Y; Xu BH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(2):76-80. PubMed ID: 21418986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
    Al-Khattabi H; Kelany A; Buhmeida A; Al-Maghrabi J; Lari S; Chaudhary A; Gari M; Abuzenadah A; Al-Qahtani M
    Anticancer Res; 2010 Oct; 30(10):4081-8. PubMed ID: 21036723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G; Godolphin W; Press MF; Slamon DJ
    Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
    Lal P; Salazar PA; Ladanyi M; Chen B
    J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of HER 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma.
    Ramadan SS; Yapicier O; Kıhtır S; Erdemır A; Doğan TH; Uskent I; Onat H; Cakmakçi M
    Turk Patoloji Derg; 2011; 27(3):196-203. PubMed ID: 21935868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
    Thompson EW; Warton K; Blick T; Wafai R; Hill P; Stanley K
    Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
    Madrid MA; Lo RW
    Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
    Mitchell MS; Press MF
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):108-16. PubMed ID: 10482202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
    Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
    J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
    Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
    J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2/neu revisited: quality and interpretive issues.
    Ahmed SS; Iqbal J; Thike AA; Lim AS; Lim TH; Tien SL; Tan PH
    J Clin Pathol; 2011 Feb; 64(2):120-4. PubMed ID: 21131629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.